

Ref. No: 0749
Date: 04/03/24
Subject: Myelofibrosis Treatment

REQUEST

1. Please provide the total number of patients treated in the last 6 months for:
 - a. Polycythaemia Vera (ICD10 code D45)
 - b. Myelofibrosis (ICD10 code D47.4)
 - c. Myelofibrosis (ICD10 code D47.4) patients aged 65 and older

2. How many patients were treated in the past 6 months (for any disease) with:
 - a. Ruxolitinib
 - b. Fedratinib
 - c. Momelotinib

3. How many patients were treated in the past 6 months for Myelofibrosis (ICD10 code D47.4) with:
 - a. Ruxolitinib
 - b. Fedratinib
 - c. Momelotinib

4. How many myelofibrosis (ICD10 code D47.4) patients has your Trust diagnosed in the past 3 years?
 - a. Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
 - b. Of these patients, how many were treated in the past 6 months with Interferon therapy?
 - c. Of these patients, how many have received no active treatment in the past 6 months?

5. Does your Trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. Please provide the total number of patients treated in the last 6 months for:

Condition	No. Patients
Polycythaemia Vera (ICD10 code D45)	105
Myelofibrosis (ICD10 code D47.4)	8
Myelofibrosis (ICD10 code D47.4) patients aged 65 and older	12

2. How many patients were treated in the past 6 months (for any disease) with:

Treatment	No. Patients
Ruxolitinib	15
Fedratinib	0
Momelotinib	<5

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

3. How many patients were treated in the past 6 months for Myelofibrosis (ICD10 code D47.4) with:

Treatment	No. Patients
Ruxolitinib	11
Fedratinib	0
Momelotinib	<5

Section 40: personal information

Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.

4. How many myelofibrosis (ICD10 code D47.4) patients has your Trust diagnosed in the past 3 years?

39 patients

a. Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?

<5 patients

Section 40: personal information

Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.

b. Of these patients, how many were treated in the past 6 months with Interferon therapy?

Nil

c. Of these patients, how many have received no active treatment in the past 6 months?

We do not hold this information centrally.

5. Does your Trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

We have not participated in any research studies involving myelofibrosis.